Drugs / selepressin
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT01612676 | Jun 2012 → Nov 2013 | infectious disease with sepsis | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01000649 | Nov 2009 → Aug 2011 | infectious disease with sepsis | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 2/31 trial · 1 missed | ||||||
| Phase 2/3 | NCT02508649 | Jul 2015 → Oct 2017 | infectious disease with sepsis | Ferring Pharmaceuticals | Terminated | Missed primary |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | selepressin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02508649 ↗ |
| Known as | FE 202158 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01000649 ↗ |
| Known as | Selepresina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1817709 ↗ |
| Known as | Selepressine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1817709 ↗ |
| Action | Activate | “Selepressin, a selective vasopressin V1a receptor agonist, is a noncatecholaminergic vasopressor that may mitigate sepsis-induced vasodilatation, vascular leakage, and edema,...” PMID 31577035 ↗ Oct 20191“Vasopressin V1a receptor agonist” CHEMBL1817709 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL1817709 ↗ |
| Target | AVPR1A | “Vasopressin V1a receptor agonist” CHEMBL1817709 ↗ |